At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 371–380 of 580 results.
-
Hyperthermic intraperitoneal chemotherapy (HIPEC) involves giving heated chemotherapy directly into the belly immediately after surgery to remove an abdominal cancer. Researchers are doing this study to see if HIPEC improves outcomes in people with ovarian cancer. The people in this study have newly diagnosed stage 3 or 4 ovarian cancer.
-
Researchers are seeking the best dose of CABA-201 to treat people with active idiopathic inflammatory myopathy (IIM). The people in this study have IIM, juvenile idiopathic inflammatory myopathy (JIIM), or myositis. With JIIM and some subtypes of IIM, B cells make the body to attack different tissues, causing inflammation and muscle weakness.
-
The purpose of this study is to assess the safety and effectiveness of the investigational immunotherapy LN-145 in patients with non-small cell lung cancer (NSCLC) that has metastasized despite prior treatment. LN-145 is called "autologous tumor infiltrating lymphocytes" (TIL) therapy. It activates white blood cells to attack the tumor.
-
Researchers want to find the best dose of STP938 to treat lymphoma and see how well this drug works against this cancer. The people in this study have B-cell or T-cell lymphoma that keeps growing even with treatment. Examples of these cancers include:
-
Gemcitabine and oxaliplatin (GemOx) is a standard chemotherapy combination used to treat a cancer of the bile ducts called cholangiocarcinoma. In this study, researchers want to see if adding another treatment that is delivered by a pump device (hepatic arterial infusion or HAI) to GemOx therapy is more effective than GemOx alone for patients with previously untreated inoperable cholangiocarcinoma. The HAI pump, which is implanted in the abdomen during a surgical procedure, continuously delivers the drugs floxuridine and dexamethasone directly to the liver.
-
The purpose of this study is to assess the safety of the investigational treatment REGN4018 alone and in combination with cemiplimab in women with ovarian, peritoneal, or fallopian tube cancer that has come back or gotten worse after previous treatment. REGN4018 is a type of drug called a bispecific antibody: it binds to two specific proteins (MUC16 and CD3) that may be involved in the growth and survival of cancer.
-
Researchers want to find the best dose of D3L-001 to treat advanced breast cancer. The people in this study have breast cancer that cannot be cured with standard therapies. Their tumors also make the HER2 protein, which plays a role in cancer growth.
-
The standard treatment for high-risk locally advanced cervical cancer is chemoradiation followed by maintenance therapy. Locally advanced means the cervical cancer has spread to nearby tissue or lymph nodes. In this study, researchers want to see if adding induction therapy before chemoradiation is more effective than standard therapy.
-
This study is assessing a new treatment approach for people with oligometastatic breast cancer. This means their cancer has spread to a small number of other parts of the body. Their cancers have high levels of the HER2 protein, which promotes breast cancer growth. In addition, they started drug therapy for their cancer and it has not gotten worse in the last 3-12 months.
-
Atezolizumab and durvalumab are standard drugs used to treat small cell lung cancer (SCLC). Researchers want to see if adding iadademstat to standard treatment helps slow SCLC growth longer than standard immunotherapies alone. The people in this study have SCLC that spread outside the lung or to other parts of the body.